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This is a case report on a 35-year-old man with acute myelogenous leukemia who 
presented fever and intermittent mucoid loose stool to the emergency center. He 
had been taking voriconazole for invasive pulmonary aspergillosis. The flexible 
sigmoidoscopy was consistent with the diagnosis of pseudomembranous colitis.
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INTRODUCTION
Diarrhea is a common complication of antimicrobial therapy and pseudomembra-
nous colitis is the most severe form of antibiotic-associated diarrhea, marked by 
endoscopic features of a white to yellow layer lining the mucosa that is typically 
most prominent in the rectum, sigmoid colon and left colon.1 Pseudomembranous 
colitis has emerged as a significant medical problem over the past few decades, be-
cause of prevalent use of broad-spectrum antibiotics. Almost all antimicrobial 
agents with antibacterial activity have been implicated; however, pseudomembra-
nous colitis after treatment with antifungal agents has rarely been reported.2 Here, 
the first case of pseudomembranous colitis which is likely associated with the anti-
fungal agent voriconazole is reported.
CASE REPORT
　　　
A 35-year-old man presented to the emergency center with fever up to 39°C for 
three days, and intermittent mucoid loose stool. The patient had previously been 
diagnosed with acute myelogenous leukemia five months ago. Two months ago, 
he underwent reinduction chemotherapy with mitoxantrone, cytarabine, and eto-
poside combination, however, failed to achieve complete remission. Fever devel-
oped during an episode of prolonged neutropenia, and imipenem/cilastatin (500 
mg qid IV) was given empirically. After 7 days, the patient was diagnosed with in-
vasive pulmonary aspergillosis and treated first with amphotericin B deoxychoate 
(9 days), then changed to caspofungin (13 days), and finally switched to voricon-Jae-Cheol Kwon, et al.
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5-days of treatment with voriconazole, 2) no other possible 
medications associated with pseudomembranous colitis at 
the time of diarrhea and 3) the improvement of symptoms 
after discontinuation of the voriconazole.
DISCUSSION
Diarrhea is one of the most common side effects of antimi-
crobial treatment, occurring in 5-25% of all patients.5 The 
onset of C. difficile diarrhea usually occurs from 4-9 days af-
ter the beginning of antibiotic therapy and pseudomembra-
nous colitis is the characteristic manifestation of full-blown 
C. difficile colitis.6 Stool tests for the diagnosis of C. difficile 
infection include cytotoxin assay, enzyme immunoassay, la-
tex agglutination assay, and culture. Although the toxin as-
say for C. difficile was negative and the stool culture for C. 
difficile was not performed in this case, a negative enzyme 
immunoassay for toxins A and B does not rule out C. diffi-
cile associated diarrhea; however, the presence of pseudo-
membranes on sigmoidoscopy is considered diagnostic.1,7,8
Voriconazole is a generally well tolerated antifungal agent 
approved for the treatment of invasive aspergillosis. Visual 
disturbances, skin rashes and elevated liver enzyme levels 
are commonly noted adverse events.9 Pseudomembranous 
colitis associated with voriconazole has not previously been 
reported; however, the available information on the drug in-
dicates it as one of the less common adverse events.10 To 
assess the objectivity, reliability and validity of causality in 
the assessment of an adverse drug reaction, the Naranjo 
probability scale and World Health Organization-Uppsala 
azole (2 days). From the beginning of treatment with the 
antifungal agents, however, the patient’s medication did not 
include antibacterials or antivirals. The patient received es-
citalopram for three months because of a major depression. 
Two days after starting voriconazole, the patient was dis-
charged without any symptoms. When he came to the 
emergency center (3 days after discharge), the medication 
included only voriconazole (200 mg bid po) and escitalo-
pram (10 mg qd po).
On examination, the patient had mild left lower quadrant 
pain without guarding or rebound tenderness. The stool ex-
amination for parasites and stool cultures for Salmonella 
and Shigella were all negative. Toxin assay for Clostridium 
difficile (C. difficile) was also negative. Flexible sigmoidos-
copy revealed edematous mucosal changes and exudates 
with yellowish plaques which were consistent with pseudo-
membranous colitis (Fig. 1). Biopsies of the plaques were 
diagnostic of pseudomembranous colitis (Fig. 2). Metronida-
zole was started orally and voriconazole was discontinued; 
the symptoms improved and the patient continued the met-
ronidazole to complete a 14-day course. After complete res-
olution of the symptoms, the patient underwent a second 
reinduction chemotherapy with amphotericin B deoxycho-
late and itraconazole for invasive pulmonary aspergillosis. 
No relapse of the pseudomembranous colitis occurred. The 
pseudomembranous colitis in this case was likely associat-
ed with the voriconazole, according to the Naranjo proba-
bility scale (6 points) and by the World Health Organization-
Uppsala Monitoring Centre causality categories.3,4
The pseudomembranous colitis was likely caused by vori-
conazole because of: 1) the sudden onset of diarrhea after 
Fig. 1. Flexible sigmoidoscopy revealed mucosal edema and yellowish exu-
dative plaques.
Fig. 2. Biopsy showed volcano-like eruptions with superficial pseudomem-
brane formation adjacent to an area of mucosal necrosis and superficial 
erosions.Pseudomembranous Colitis after Voriconazole Therapy
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Monitoring Centre causality categories were used in this 
case.3,4 This patient developed pseudomembranous colitis 
5-days after the treatment with voriconazole, was taking no 
other medications associated with pseudomembranous coli-
tis at diagnosis, and improved after discontinuation of the 
voriconazole and initiation of oral metronidazole. The ad-
verse event was confirmed by sigmoidoscopy; rechallenge 
was not performed. Overall, voriconazole showed a probable 
relationship with pseudomembranous colitis, according to 
both the Naranjo probability scale (6 points) and the World 
Health Organization-Uppsala Monitoring Centre causality 
categories.
There has been only one report on pseudomembranous 
colitis associated with the antifungal agent itraconazole.2 As 
this case indicated, antifungal agents may alter the microbial 
flora of the colon without direct activity against bacteria.2 
Fungi, particularly Candida albicans, are considered micro-
flora of the normal adult gastrointestinal tract,11 therefore, it is 
likely that the voriconazole altered the normal intestinal mi-
croflora followed by C. difficile exposure and colonization, 
resulting in mucosal injury of the colon and inflammation due 
to toxins, and finally the development of pseudomembranous 
colitis. Heard, et al.12 reported that acute leukemia or its treat-
ment constitutes a significant risk factor for acquisition of C. 
difficile. This patient developed pseudomembranous colitis 
after remission induction chemotherapy for acute myeloge-
nous leukemia and this might have been an important addi-
tional factor associated with C. difficile colonization.
In summary, the present case suggests that pseudomem-
branous colitis may result from alteration of the fungal flora 
as well as bacterial microflora of the intestine, and that anti-
fungal agents should be considered as a rare but possible 
cause of pseudomembranous colitis.
 